Categories Uncategorized

How to Address Various Health Inequities Using Digital Technologies

Digital technologies can be used to address various determinants of health by helping dismantle inequity. Below are a few factors of inequity that can be addressed by digital technologies.

  • Unequal support for high medical expenses

Every year, more than 900 million individuals spend roughly 10% of their household budget on healthcare expenses. Of this number, about 100 million are pushed into poverty because of this.

While government financial schemes and health insurance are important protections for people, they aren’t widely available to marginalized communities. Digital financial services can help lay the groundwork for accessible insurance schemes which hinder catastrophic medical expenses that cause poverty, as part of efforts to attain universal health coverage.

  • Unequal representation in public health services and systems

The data collected by information systems doesn’t always equitably represent populations. Data that is not inclusive or representative will produce inequitable results.

However, digital technologies that are thoughtfully designed can be used to increase access to health services for people who would otherwise be deprived of care, as well as improve representation in health system data.

In addition to this, digital tools may also be used to reach more individuals and connect with those who may not have found ways to access important health services that feel comfortable and safe.

  • Unequal access to medical commodities

The availability of crucial medical commodities such as devices, diagnostics, vaccines and medicines has an impact on the quality of care delivered.

As we’ve observed during the coronavirus pandemic, lack of equitable access to essential commodities such as medical oxygen has huge consequences. Digital approaches and tools could be used to offer better data to forecast and address shortages in supply when they occur, as well as streamline chains of supply.

  • Unequal access to medical expertise

Estimates show that by the year 2030, the global health sector will need almost 20 million additional health workers in order to attain universal health coverage. This shortage in the healthcare workforce isn’t shared equally among communities. Digital approaches and tools can be used to offer new ways to address this gap, as well as extend the skills and reach of the current workforce.

  • Unequal access to reliable health data

Lack of timely and high-quality information can result in ineffective health interventions, wasted resources and even an increase in the health equity gap. Digital tools can be used to address and meet this need.

Many believe that the digital transformation of health systems spells doom for those employed in the healthcare sector. On the contrary, digital tools help support health systems, enabling the provision of better health services. This is why we should work towards expanding the digital health community.

Many companies, including RYAH Group Inc. (CSE: RYAH), have also stepped up to bring innovations such as the RYAH MD platform intended to facilitate virtual interactions between doctors and their patients. Such technologies will ease the transition to remote health.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Deadly Infection Surges, Prompts Health Officials to Caution Beachgoers

Beachgoers on the Gulf Coast in the U.S. have been urged to exercise caution in order to limit…

14 hours ago

Earth Science Tech Inc. (ETST) Q1 2027 Financial and Operational Results Reflect Compounding Progress of Expansion Strategy

Earth Science Tech, a growing healthcare holding company, recently reported its Q1 2027 financial results,…

15 hours ago

Spanish Patient Highlights Risks of Poorly Cooked Pork

Doctors in Spain recently handled a fascinating yet terrifying case of a patient that developed brain cancer-like symptoms and…

5 days ago

Liquid Biopsy Forecasts Response to Immunotherapy in Lung Cancer Patients

While immunotherapy is revolutionizing cancer therapy, response rates to these novel treatments are low and some patients…

6 days ago

Surgeon, Payer, Patient Win: The Economic and Workflow Advantages Positioning GelrinC as a New Standard of Care for Knee Cartilage Repair

Regentis recently received European regulatory approval for a next-generation GelrinC manufacturing process that increases production…

6 days ago

VERAXA Biotech AG (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies 

The company has advanced its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program into the next stage…

7 days ago